

Spire Healthcare Group plc

2025 Annual Report and Notice of 2026 Annual General Meeting

9 April 2026

Spire Healthcare Group plc (LSE: SPI) ('Spire Healthcare', 'the Group' or 'the Company'), a leading independent healthcare group in the UK, announced its preliminary results for the year ended 31 December 2025 ('Preliminary Announcement') on Thursday, 5 March 2026.

Further to the Preliminary Announcement, the Company confirms that its Annual Report and Accounts for the year ended 31 December 2025 (the '2025 Annual Report'), the Notice of 2026 Annual General Meeting and Form of Proxy have now been published. Printed copies have been posted to shareholders who have requested hard copies.

The following documents are now available on the Company's website and can be accessed via investors.spirehealthcare.com:

- 2025 Annual Report
- Notice of 2026 Annual General Meeting

In accordance with UK Listing Rule 6.4.1R, the Company will submit its 2025 Annual Report and other shareholder documents to the National Storage Mechanism. These documents will be available for inspection shortly at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

In accordance with the Disclosure and Transparency Rules ('DTRs') the regulated information required to be communicated under DTR 6.3.5R(1A) is available in unedited full text within the 2025 Annual Report which will be available both on the National Storage Mechanism and on the Company's website at investors.spirehealthcare.com.

Arrangements for the Annual General Meeting

The Annual General Meeting of the Company will be held at 11.00am on Thursday, 14 May 2026 at 3 Dorset Rise, London EC4Y 8EN (the '2026 AGM').

The Company welcomes shareholders to attend the 2026 AGM in person, but they are asked to monitor the Company's website should any changes in requirements on attending the meeting be necessary.

The Board always welcomes questions from shareholders, and we request that these are submitted by e-mail to companysecretary@spirehealthcare.com. A summary of questions and responses will be put on the Company's website ahead of the meeting.

Details of the resolutions to be proposed at the 2026 AGM are set out in the Notice of 2026 Annual General Meeting. The voting results of all resolutions put before the 2026 AGM will be announced to the market following the meeting.

ENQUIRIES:

For further information please contact:

Spire Healthcare Group plc

Mantraraj Budhdev
Group General Counsel, Chief People Officer and
Company Secretary

0800 169 1777
companysecretary@spirehealthcare.com

Amie Gramlick
Director of Commercial Finance and Investor Relations 0800 169 1777
investors@spirehealthcare.com

About Spire Healthcare

[Spire Healthcare](#) is a leading, independent healthcare group in the United Kingdom, running 38 hospitals and over 60 clinics across England, Wales and Scotland. Working in partnership with over 8,800 experienced consultants, Spire Healthcare delivered tailored, personalised care to over 1.36 million inpatients, outpatients and day case patients, and workplace health clients, in 2025. It is the leading private provider, by volume, of [knee](#) and [hip](#) operations in the United Kingdom.

It operates a network of private GPs and provides workplace health services to over 1,400 employers. It also delivers a range of private, NHS and employer-funded mental health, musculoskeletal and dermatological services, and is the largest independent provider of NHS talking therapies in England.

Spire Healthcare's almost 100 well-located clinical sites deliver award-winning care for self-pay patients, the NHS, employers and private medical insurance ('PMI') providers. 98% of Spire Healthcare's inspected locations are rated 'Good,' 'Outstanding', or the equivalent by health inspectors in England, Wales and Scotland.

Spire Healthcare is listed on the London Stock Exchange and is a member of the FTSE 250.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAUKSARNNUSRAR